It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mutations in KCNC3, which encodes the Kv3.3 potassium channel, cause degeneration of the cerebellum, but exactly how the activity of an ion channel is linked to the survival of cerebellar neurons is not understood. Here, we report that Kv3.3 channels bind and stimulate Tank Binding Kinase 1 (TBK1), an enzyme that controls trafficking of membrane proteins into multivesicular bodies, and that this stimulation is greatly increased by a disease-causing Kv3.3 mutation. TBK1 activity is required for the binding of Kv3.3 to its auxiliary subunit Hax-1, which prevents channel inactivation with depolarization. Hax-1 is also an anti-apoptotic protein required for survival of cerebellar neurons. Overactivation of TBK1 by the mutant channel leads to the loss of Hax-1 by its accumulation in multivesicular bodies and lysosomes, and also stimulates exosome release from neurons. This process is coupled to activation of caspases and increased cell death. Our studies indicate that Kv3.3 channels are directly coupled to TBK1-dependent biochemical pathways that determine the trafficking of cellular constituents and neuronal survival.
How the activity of the neuronal Kv3.3 voltage-dependent channel is regulated is unclear. Here, the authors show that the known Kv3.3 channel complex with Hax1, which affects spinal cerebellar ataxia, regulates the enzyme Tank Binding Kinase 1, modulating survival of cerebellar neurons.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Henao-Mejia, Jorge 4 ; D’Acunzo Pasquale 5
; Levy, Efrat 6 ; Flavell, Richard A 7
; Horvath, Tamas L 2
; Kaczmarek, Leonard K 8
1 Yale University School of Medicine, Department of Pharmacology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
2 Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
3 Yale University School of Medicine, Department of Immunobiology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); The Jackson Laboratory, The Jackson Laboratory for Genomic Medicine, Farmington, USA (GRID:grid.249880.f) (ISNI:0000 0004 0374 0039)
4 Yale University School of Medicine, Department of Immunobiology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); University of Pennsylvania, Children’s Hospital of Philadelphia, Department of Pathology and Laboratory Medicine, Institute for Immunology, Perelman School of Medicine, Philadelphia, USA (GRID:grid.47100.32)
5 The Nathan S. Kline Institute for Psychiatric Research, Center for Dementia Research, Orangeburg, USA (GRID:grid.250263.0) (ISNI:0000 0001 2189 4777); New York University School of Medicine, Department of Psychiatry, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
6 The Nathan S. Kline Institute for Psychiatric Research, Center for Dementia Research, Orangeburg, USA (GRID:grid.250263.0) (ISNI:0000 0001 2189 4777); New York University School of Medicine, Department of Psychiatry, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); New York University School of Medicine, NYU Neuroscience Institute, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); New York University School of Medicine, Department of Biochemistry & Molecular Pharmacology, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
7 Yale University School of Medicine, Department of Immunobiology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Howard Hughes Medical Institute, Chevy Chase, USA (GRID:grid.413575.1) (ISNI:0000 0001 2167 1581)
8 Yale University School of Medicine, Department of Pharmacology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale School of Medicine, Department of Cellular and Molecular Physiology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)




